南宫NG·28(中国)相信品牌力量

Shenzhen, China – From December 16 to December 18, MicroPort Endovascular (Shanghai) Co., Ltd.("MicroPort® Endovascular") attended the Sixth China Shenzhen International Cardiovascular Disease Forum & China Cardiovascular Surgery Technique and Engineering Conference in Shenzhen to display CRONUS™ Surgical Stent-Graft System ("CRONUS™") and other innovative products.

During the conference, many domestic and international experts of cardiac surgery were invited for academic exchange with the purpose of learning the latest innovation and proactively seeking for improvement. Specifically, the three-day conference provided a platform for sharing the updated academic advancement and clinical experience through lectures, panel discussions, case studies and operation demonstrations.

During the session of Interventional Treatment and Open Surgery for Aortic Disease held on December 18, Professor Weiguo Ma of Beijing Anzhen Hospital delivered a speech on "Surgical Stent for Elephant Trunk Procedure: Innovative Stent and Application Outcome," in which he compared several kinds of stent products used in the elephant trunk procedure. According to statistics, as of December 2016, over 23,000 CRONUS™ have been implanted worldwide, far more than any product of its kind. Professor Weiguo Ma pointed out, an ideal surgical stent for the elephant trunk procedure should have the following features: wide scope of indications, easy operation, no need of perspective and guide wire, excellent match with aortic wall, outstanding flexibility, stent graft with tapered size and good biocompatibility. As China's only stent-graft used in the elephant trunk procedure, CRONUS™ offers simpler treatment by combining traditional open surgery and advanced interventional approaches, which significantly reduces the surgical trauma and risk, alleviate suffering for patients and improves surgical success rate.

In addition, MicroPort® Endovascular displayed its innovative products including CRONUS™, Hercules™-T Low Profile Stent Graft System, and Castor™ Branched Aortic Stent Graft System, and meanwhile fully demonstrated their features, advantages and application procedures by face-to-face communication and product brochure interpretation. Many attended experts were attracted to visit MicroPort® Endovascular booth and some of them had in-depth discussion with our R&D staffs in terms of product features and surgical techniques based on their own surgical experience. In the future, MicroPort® Endovascular will stick to our innovative product R&D and further diversify our product portfolio to offer more high-quality endovascular products for patients.